Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Kalinowski, Felicity C ^a   Giles, Keith M ^a   Candy, Patrick A ^a,b   Ali, Alishum ^a   Ganda, Clarissa ^a   Epis, Michael R ^a   Webster, Rebecca J ^a   Leedman, Peter J ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MESSENGER RNA; MICRORNA; MICRORNA 7; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; GENE CONTROL; GENE FUNCTION; GENE TARGETING; GENETIC TRANSFECTION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN RNA BINDING; REGULATORY MECHANISM; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

3' UNTRANSLATED REGIONS; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HUMANS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84868113137     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047067     Document Type: Article

References (63)

1. Baba Y, Fujii M, Tokumaru Y, Kato Y (2012) Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer. Journal of Oncology 2012.
2. Loeffler-Ragg J, Schwentner I, Sprinzl GM, Zwierzina H, (2008) EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert Opin Investig Drugs 17: 1517-1531.
3. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker J, et al. (2006) Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24: 4170-4176.
4. Testa JR, Bellacosa A, (2001) AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 98: 10983-10985.
5. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
6. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, et al. (2001) Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 61: 6500-6510.
7. Lewis TS, Shapiro PS, Ahn NG, (1998) Signal transduction through MAP kinase cascades. Adv Cancer Res 74: 49-139.
8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578.
9. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127.
10. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, et al. (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987.
11. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, et al. (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77-85.
12. Bauman JE, Michel LS, Chung CH (2012) New promising molecular targets in head and neck squamous cell carcinoma. Curr Opin Oncol.
13. Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, et al. (2011) Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat 14: 260-279.
14. Wheeler DL, Dunn EF, Harari PM, (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7: 493-507.
15. Cuellar TL, McManus MT, (2005) MicroRNAs and endocrine biology. J Endocrinol 187: 327-332.
16. Uhlmann S, Mannsperger H, Zhang JD, Horvat EA, Schmidt C, et al. (2012) Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol 8: 570.
17. Farazi TA, Spitzer JI, Morozov P, Tuschl T, (2011) miRNAs in human cancer. J Pathol 223: 102-115.
18. Chang SS, Jiang WW, Smith I, Poeta LM, Begum S, et al. (2008) MicroRNA alterations in head and neck squamous cell carcinoma. Int J Cancer 123: 2791-2797.
19. Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, et al. (2009) Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cell carcinoma. Am J Pathol 174: 736-745.
20. Wong TS, Liu XB, Wong BY, Ng RW, Yuen AP, et al. (2008) Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue. Clin Cancer Res 14: 2588-2592.
21. Tran N, McLean T, Zhang X, Zhao CJ, Thomson JM, et al. (2007) MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 358: 12-17.
22. Iorio MV, Croce CM, (2012) MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 4: 143-159.
23. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, et al. (2008) microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572.
24. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, et al. (2009) Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284: 5731-5741.
25. Reddy SD, Ohshiro K, Rayala SK, Kumar R, (2008) MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 68: 8195-8200.
26. Kwok TT, Sutherland RM, (1991) Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer 64: 251-254.
27. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, et al. (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85-94.
28. Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL, et al. (2004) Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res 10: 7764-7774.
29. Huntzinger E, Izaurralde E, (2011) Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet 12: 99-110.
30. Fang YX, Xue JL, Shen Q, Chen J, Tian L (2012) miR-7 inhibits tumor growth and metastasis by targeting the PI3K/AKT pathway in hepatocellular carcinoma. Hepatology.
31. Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, et al. (2011) Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther 10: 1720-1727.
32. Saydam O, Senol O, Wurdinger T, Mizrak A, Ozdener GB, et al. (2011) miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res 71: 852-861.
33. Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, et al. (2007) Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 6: 2664-2674.
34. Bliss C, (1939) The toxicity of poisons applied jointly. Annals of Applied Biology 26: 585-615.
35. Parker BJ, Wen J, (2009) Predicting microRNA targets in time-series microarray experiments via functional data analysis. BMC Bioinformatics 10Suppl 1: S32.
36. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, et al. (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69: 3021-3031.
37. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
38. Hickinson DM, Marshall GB, Beran GJ, Varella-Garcia M, Mills EA, et al. (2009) Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib. Clin Transl Sci 2: 183-192.
39. Tanida S, Joh T, Itoh K, Kataoka H, Sasaki M, et al. (2004) The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology 127: 559-569.
40. O-Charoenrat P, Modjtahedi H, Rhys-Evans P, Court WJ, Box GM, et al. (2000) Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 60: 1121-1128.
41. Kong D, Piao YS, Yamashita S, Oshima H, Oguma K, et al. (2011) Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene.
42. Miyata Y, Nishida E, (2005) CK2 binds, phosphorylates, and regulates its pivotal substrate Cdc37, an Hsp90-cochaperone. Mol Cell Biochem 274: 171-179.
43. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, et al. (2005) Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12: 668-677.
44. Bliesath J, Huser N, Omori M, Bunag D, Proffitt C, et al. (2012) Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells. Cancer Lett.
45. Mut M, Lule S, Demir O, Kurnaz IA, Vural I, (2012) Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells. Int J Biochem Cell Biol 44: 302-310.
46. Kwon CY, Kim KR, Choi HN, Chung MJ, Noh SJ, et al. (2010) The role of serum response factor in hepatocellular carcinoma: implications for disease progression. Int J Oncol 37: 837-844.
47. Barr S, Thomson S, Buck E, Russo S, Petti F, et al. (2008) Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions. Clin Exp Metastasis 25: 685-693.
48. Kong X, Li G, Yuan Y, He Y, Wu X, et al. (2012) MicroRNA-7 Inhibits Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer Cells via Targeting FAK Expression. PLoS One 7: e41523.
49. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, et al. (2008) Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 105: 13021-13026.
50. Jiang L, Liu X, Chen Z, Jin Y, Heidbreder CE, et al. (2010) MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochem J 432: 199-205.
51. Epis MR, Barker A, Giles KM, Beveridge DJ, Leedman PJ, (2012) The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem 286: 41442-41454.
52. Lee KM, Choi EJ, Kim IA, (2011) microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 101: 171-176.
53. Duex JE, Comeau L, Sorkin A, Purow B, Kefas B, (2011) Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. J Biol Chem 286: 25377-25386.
54. Easty DM, Easty GC, Carter RL, Monaghan P, Butler LJ, (1981) Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck. Br J Cancer 43: 772-785.
55. Rangan SR, (1972) A new human cell line (FaDu) from a hypopharyngeal carcinoma. Cancer 29: 117-121.
56. Rheinwald JG, Beckett MA, (1981) Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res 41: 1657-1663.
57. Giles KM, Barker A, Zhang PM, Epis MR, Leedman PJ, (2011) MicroRNA regulation of growth factor receptor signaling in human cancer cells. Methods Mol Biol 676: 147-163.
58. McFarland DC, (2000) Preparation of pure cell cultures by cloning. Methods Cell Sci 22: 63-66.
59. Wang X, Seed B, (2003) A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 31: e154.
60. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
61. Tomayko MM, Reynolds CP, (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24: 148-154.
62. Becker RA, Chambers JM, Wilks AR (1988) The New S Language: A Programming Environment for Data Analysis and Graphics.
63. Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, et al. (2010) TGF-Î2 IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proceedings of the National Academy of Sciences.